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Does screening reduce  
lung cancer mortality?
It’s	not	clear.	neither	routine	chest	x-ray	
(with	or	without	sputum	cytology)	nor	low-
dose	computed	tomography	(CT)	have	
been	proven	to	reduce	mortality	when	
used	for	lung	cancer	screening,	although	
low-dose	CT	screening	does	identify	lung	
cancer	at	an	early	stage	in	high-risk	patients	
(strength	of	recommendation:	B,	based	on	
heterogeneous	cohort	studies).	large	studies	
of	both	imaging	approaches	are	ongoing.
Let’s prevent lung cancer so we don’t 
have to worry about screening
While	some	trials	suggest	possibly	useful	
screening	tools,	and	myriad	other	trials	are	
underway,	one	point	often	gets	short	shrift:	
the	importance	of	preventing	cancer	from	
occurring	in	the	first	place.	Most	family	
physicians	already	screen	for	smoking	
and	offer	counseling	and	pharmacologic	
assistance	to	smokers.	We	should	also	be	
aggressively	counseling	our	adolescent	
and	young	adult	patients	against	starting	
to	smoke.	Ideally,	we	would	help	people	
reduce	their	exposure	to	secondhand	
smoke,	as	well.	When	a	teachable	moment	
comes	along,	we	should	take	the	time	to	
educate	our	patients	about	their	specific	
risk	factors	and	how	they	can	be	modified.	
Preventing	the	problem	before	it	starts	is	our	
patients’	best	defense	against	lung	cancer.
 
Tim Huber, MD
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z Evidence summary
Chest x-ray and cytology:  
A trend toward reduced mortality
A Cochrane review1 identified 6 ran-
domized controlled trials (RCTs) and 
1 non-RCT (with a total of 245,610 
patients) that screened patients with se-
rial chest x-rays, with or without sputum 
cytology. Most patients were current or 
ex-smokers or had significant exposure 
to industrial smoke. No studies included 
an unscreened control group, and only 
1 included women. 
There was a trend toward reduced 
mortality with the combination of an-
nual chest x-ray and sputum cytology 
compared with annual x-ray alone, but 
it was not statistically significant (relative 
risk [RR]=0.88; 95% confidence interval 
[CI], 0.74–1.03). However, more frequent 
screening with chest x-rays (2 or 3 times/
year) was associated with an 11% increase 
in mortality compared with less frequent 
x-rays (RR=1.11; 95% CI, 1.00–1.23). 
The authors concluded that there was in-
sufficient evidence to support screening 
with chest x-ray or sputum cytology. 
Low-dose CT: Studies reach  
different conclusions
A 2006 study followed a cohort of at-risk 
patients using low-dose CT screening.2 
Clinical commentary
Evidence-based answer
fast track
Low-dose CT 
screening does 
identify lung  
cancer at an early 
stage in high-risk 
patients
ConT InueD
Lung carcinoma on CT scan
fast track
C
l
in
iC
a
l
 I
n
q
u
Ir
Ie
s
50 vol	57,	no	1	/	january	2008		ThE JournaL of famiLy PraCTiCE
There were 31,567 patients evaluated 
initially, of which 27,456 had an annual 
repeat screening. Most patients were cur-
rent or former smokers (83%); patients 
with exposure to occupational and sec-
ondhand smoke were also included. A 
positive initial screen was defined as a 
solid or partly solid noncalcified nodule 
≥5 mm in diameter; a nonsolid, noncalci-
fied nodule ≥8 mm in diameter; or a solid 
endobronchial nodule. A positive screen 
during follow-up was defined as any new 
noncalcified nodule, regardless of size. 
Positive tests occurred in 13% of 
baseline screens and 5% of annual 
screens. Biopsies were performed accord-
ing to a study protocol based on a nod-
ule’s size and behavior over time. Out of a 
total of 5646 positive screens, there were 
535 biopsies, and a diagnosis of cancer in 
492 patients. Of those with cancer, 412 
(84%) had clinical stage I lung cancer; the 
authors estimated their 10-year survival 
rate was 88% (95% CI, 84%–91%). If 
patients with stage I disease underwent 
surgical resection within 1 month of di-
agnosis, their estimated 10-year survival 
increased to 92% (95% CI, 88%–95%).
However, a cohort study using an-
nual CT scanning to screen 3246 pa-
tients for lung cancer came to a different 
conclusion.3 The authors compared the 
observed number of lung cancer cases, re-
sections, advanced lung cancer diagnoses, 
and deaths in screened patients with the 
expected rates based on validated predic-
tion models. Lung cancer was diagnosed 
in 144 patients compared with 44 expect-
ed cases (RR=3.2; 95% CI, 2.7–3.8). Sub-
sequently, 109 patients underwent lung 
resection compared with 11 expected 
(RR=10.0; 95% CI, 8.2–11.9). However, 
there was no decline in advanced cancers 
(42 actual vs 33 expected; P=.14) and no 
difference in deaths due to lung cancer 
(38 actual vs 38.8 expected; P=.9). The 
81 patients diagnosed in this study with 
stage I disease who underwent surgical 
resection had 4-year estimated survival 
rates of 94% (95% CI, 85%–97%), 
matching the prior low-dose CT study.
Major studies of both methods  
are ongoing
Other major studies are in progress. 
There is an RCT involving 154,942 male 
and female patients using annual chest 
x-ray screening vs no screening that will 
involve 14 years of follow-up.4 Another 
RCT is evaluating annual low-dose CT vs 
annual chest x-ray for 3 years in 50,000 
at-risk men and women.5 Finally, investi-
gators are conducting an RCT with 4000 
at-risk patients comparing annual CT 
screening with no screening.6
Recommendations from others 
The US Preventive Services Task Force 
gives an “I” recommendation (data in-
sufficient) to screening for lung cancer 
with cytology, chest x-ray, or CT scan-
ning.7 The American College of Chest 
Physicians stated in 2003 that the early 
studies of low-dose CT appeared prom-
ising; however, they recommended that 
individuals should only be screened 
with low-dose CT in the context of well- 
designed clinical trials.8   n
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Screening for lung 
cancer with x-ray, 
cytology, or CT 
scan is rated  
“I” for insufficient 
data by the USPSTF 
